Second-generation Bruton s tyrosine kinase inhibitors are a great frontline option for most, if not all, patients with chronic lymphocytic leukemia (CLL), owing to their improved toxicity profiles.
Black patients with cancer are significantly more likely to experience heart damage following chemotherapy than White patients are, a research review indicates.
The atezolizumab-bevacizumab combination is the first to show efficacy in the adjuvant setting after HCC resection for patients at high risk for recurrence, but the overall survival benefit is unclear.
The report 'Antibody conjugates for targeted delivery of Toll-like receptor 9 agonist to the tumor tissue', published in the PLOS ONE journal, highlights MHRA research which showed that genetic engineering of antibodies used to activate and support the immune system against cancer leads to improvements in their reliability and effectiveness.